Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2010 Mar 1.

Published in final edited form as: Am J Kidney Dis. 2008 Dec 19;53(3):426–437. doi: 10.1053/j.ajkd.2008.09.024

Higher performing hospitals were also found to have higher rates of prescribing for each of the 4 guideline-recommended discharge medications: aspirin (2a), clopidogrel (2b), lipid-lowering agent (2c), and ACE inhibitor (2d). For most therapies (2a, 2b, 2c), an eGFR effect was present in the leading but not the lagging hospital rank groups. An eGFR effect was present in the lagging but not the leading hospital rank groups for ACE inhibitor use (Fig 2d), a pattern consistent with the initial study hypothesis that higher performing hospitals would have higher rates of prescribing at all levels of eGFR, mitigating the pattern of underuse commonly found as eGFR declines.

Higher performing hospitals were also found to have higher rates of prescribing for each of the 4 guideline-recommended discharge medications: aspirin (2a), clopidogrel (2b), lipid-lowering agent (2c), and ACE inhibitor (2d). For most therapies (2a, 2b, 2c), an eGFR effect was present in the leading but not the lagging hospital rank groups. An eGFR effect was present in the lagging but not the leading hospital rank groups for ACE inhibitor use (Fig 2d), a pattern consistent with the initial study hypothesis that higher performing hospitals would have higher rates of prescribing at all levels of eGFR, mitigating the pattern of underuse commonly found as eGFR declines.